SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Transgene Biotek receives patent for liver cancer molecule in US

07 Jul 2015 Evaluate

Transgene Biotek has received patent in the US for its novel molecule to be developed for treatment of liver cancer. The company’s novel molecule ‘miRNA 101’ for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed.

The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics. This granting of USA patent is a significant step in moving ahead with the development of this novel drug.

Transgene Biotek is involved in the development of several cutting edge technologies. The company is engaged in manufacturing drugs for New Drug Delivery System (NDDS), Biogeneries and Human Vaccines.



Transgene Biotek Share Price

2.99 0.00 (0.00%)
22-Apr-2026 13:21 View Price Chart
Peers
Company Name CMP
Syngene Internation. 433.30
Indegene 492.35
CMS Info Systems 313.55
JITF Infralogistics 323.00
Sagility 41.61
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×